HHS Opens Path to Compound BPC-157, TB-500 & More Peptides

If you have been following peptide therapy — or searching for BPC-157 or TB-500 anywhere in the U.S. — you already know the biggest barrier has been regulation, not science. For years, these peptides were not FDA-approved medications and were not cleared for pharmacy compounding, which made it impossible for licensed U.S. pharmacies to prepare them legally. Today that changed: the federal government opened a temporary path for pharmacies to compound these peptides, reopening a legal, regulated route to access. At Lean Lab, we have been watching this closely — here is what it actually means.

What Actually Changed Today

On October 28, 2026, the U.S. Department of Health and Human Services — led by Secretary Robert F. Kennedy Jr. — announced it will use enforcement discretion — temporarily declining to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians that compound six peptides not FDA-approved as drugs. A few important specifics:

• It is an enforcement discretion policy — HHS is temporarily declining to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians that compound these peptides. It functions as a bridge while the FDA decides whether to formally clear them for the 503A Bulks List.
• It covers six named peptides — BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — the same six compounds featured in our peptide programs.
• It includes safety requirements — Compounding pharmacies operating under the policy are expected to meet pharmacy quality standards and report adverse events.
• It was contested inside the agency — Some FDA staff scientists had recommended against expanded access, and the advisory committee's votes went against the agency reviewers' recommendations. Coverage of the announcement has been critical as well as celebratory — which is exactly why we are laying out the facts here.

Why These Peptides Were Off-Limits

Under federal law, U.S. pharmacies that prepare customized medications operate under Section 503A of the Food, Drug & Cosmetic Act. To decide which bulk ingredients those pharmacies may use, the FDA maintains a list of bulk drug substances — Category 1 substances may be compounded, while Category 2 substances the agency has flagged for significant safety risks cannot. These peptides had been neither FDA-approved drugs nor cleared for compounding, so U.S. pharmacies could not legally prepare them — the situation many people shorthand as the do-not-compound list.

A peptide's restricted status was never a verdict that the peptide does not work. It was a regulatory classification — but its practical effect was the same: patients could not access these compounds through a licensed medical provider and a U.S. pharmacy, and gray-market overseas sellers filled the gap with products of unknown purity.

The Road Here

Today's announcement did not come out of nowhere. Here is the sequence:

• July 23, 2026— FDA's Pharmacy Compounding Advisory Committee met and voted to recommend six of seven nominated peptides for inclusion on the 503A Bulks List — including BPC-157, KPV, TB-500, and MOTS-c — over the objections of FDA staff scientists.
• October 2026— An interim peptide compounding policy moved through White House regulatory review.
• October 28, 2026— HHS Secretary Kennedy announced the enforcement discretion policy opening compounding access to the six peptides, ahead of formal list changes.

Which Peptides Does This Cover?

The six peptides named in today's policy are the same compounds we now feature in our peptide programs. Everything below describes what researchers are studying these compounds for — not treatment claims:

What This Does NOT Mean

This is important, and we will not overstate it: the announcement is not FDA approval. These peptides are still not FDA-approved medications, and most of the research behind them remains early-stage or preclinical. The policy is enforcement discretion — the FDA is still weighing its formal decision on the Bulks List, and the rules could change. A prescription from a licensed provider is still required. What changed is the regulatory pathway: these compounds can now be prepared legally by U.S. pharmacies and provided under medical supervision, which is how medicine should work.

If you see anyone selling these peptides online without a prescription, that is still not a legitimate route — and it never was. The safe path is the same one we have always recommended: a provider who knows your history, quality-sourced compounds, and follow-up.

Frequently Asked Questions

What did the FDA announce today about peptides?

On October 28, 2026, HHS — led by Secretary Robert F. Kennedy Jr. — announced it will use enforcement discretion — temporarily declining to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians that compound six peptides not FDA-approved as drugs: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. The FDA is still weighing formal changes to the 503A Bulks List.

Were these peptides removed from the do-not-compound list?

Not formally. The FDA's 503A Bulks List has not been amended; what changed is a temporary policy permitting compounding ahead of formal rulemaking. Many headlines shorthand this as removing them from the do-not-compound list, because the practical effect is the same: licensed U.S. pharmacies can now compound them with a prescription.

Does this mean peptides are now FDA-approved?

No. The temporary policy permits licensed pharmacies to compound these peptides with a prescription. It does not make them FDA-approved medications, and most of the research remains early-stage or preclinical.

Can I get BPC-157 or TB-500 with a prescription at Lean Lab?

Possibly, yes. We prescribe peptides through U.S. 503A compounding pharmacy partners when clinically appropriate, and our pharmacy partners are evaluating the new policy. Availability is confirmed by your provider at consultation based on your goals, labs, and health history.

Want to Know What This Means for You?

The best first step is a conversation. Lean Lab is a peptide therapy clinic in Pasadena serving the greater Los Angeles area, and here is what a consultation actually covers:

• A provider reviews your health history, labs, and goals one-on-one
• We walk through which compounds are accessible under the new policy — and which are not yet
• Any prescription goes through licensed U.S. 503A compounding pharmacies, never gray-market sellers
• You get ongoing follow-up and dose oversight, not a one-time shipment

Explore our full peptide programs, or book a consultation and let our medical team build a plan around your biology.